Oak Ridge Investments LLC Sells 3,134 Shares of Urogen Pharma $URGN

Oak Ridge Investments LLC trimmed its holdings in Urogen Pharma (NASDAQ:URGN) by 4.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 70,570 shares of the company’s stock after selling 3,134 shares during the quarter. Oak Ridge Investments LLC owned approximately 0.15% of Urogen Pharma worth $967,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in URGN. RA Capital Management L.P. bought a new position in Urogen Pharma in the 1st quarter worth approximately $35,461,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Urogen Pharma by 216.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock worth $48,227,000 after purchasing an additional 2,983,368 shares during the period. Vestal Point Capital LP boosted its stake in Urogen Pharma by 32.1% in the 1st quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company’s stock worth $23,812,000 after purchasing an additional 522,957 shares during the period. SG Americas Securities LLC boosted its stake in Urogen Pharma by 701.8% in the 1st quarter. SG Americas Securities LLC now owns 162,514 shares of the company’s stock worth $1,797,000 after purchasing an additional 142,245 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its stake in Urogen Pharma by 14.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 786,472 shares of the company’s stock worth $8,698,000 after purchasing an additional 100,000 shares during the period. 91.29% of the stock is currently owned by institutional investors.

Urogen Pharma Stock Up 1.6%

Shares of URGN opened at $16.68 on Monday. The company has a market cap of $771.68 million, a PE ratio of -5.02 and a beta of 1.00. The business has a fifty day moving average of $18.78 and a 200 day moving average of $13.88. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $21.71.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.23). The company had revenue of $24.22 million during the quarter, compared to the consensus estimate of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. As a group, research analysts anticipate that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 1,520 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $19.11, for a total value of $29,047.20. Following the sale, the general counsel owned 43,305 shares in the company, valued at $827,558.55. This trade represents a 3.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $17.69, for a total value of $176,900.00. Following the completion of the sale, the insider owned 148,229 shares in the company, valued at approximately $2,622,171.01. The trade was a 6.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,265 shares of company stock worth $502,236 over the last quarter. Company insiders own 4.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on URGN. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of Urogen Pharma in a research note on Friday, October 3rd. HC Wainwright lowered their target price on Urogen Pharma from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Piper Sandler began coverage on Urogen Pharma in a research report on Monday, August 18th. They set an “overweight” rating and a $36.00 target price for the company. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $32.00.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.